Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
[225Ac]Ac-AKY-1189 (therapeutic)
Aktis Oncology
Urothelial Carcinoma Bladder
1 trial -
[225Ac]Ac-AKY-2519 (therapeutic)
Aktis Oncology
Castration Resistant Metastatic Prostate Cancer
1 trial -
ateganosine
MAIA Biotechnology
Resectable Hepatocellular Carcinoma
1 trial -
cannabis
BRIGHT MINDS BIOSCIENCES INC.
Behavioral Pharmacology of Cannabis
1 trial -
evorpacept
ALX ONCOLOGY HOLDINGS INC
Higher Risk Myelodysplastic Syndromes
1 trial -
evorpacept
ALX ONCOLOGY HOLDINGS INC
Acute Myeloid Leukemia
1 trial -
neratinib
PUMA BIOTECHNOLOGY, INC.
Healthy
5 trials -
neratinib
PUMA BIOTECHNOLOGY, INC.
Tumors
1 trial -
questionnaires
Cardiff Oncology
Anxiety
1 trial -
ziftomenib
Kura Oncology
Gastrointestinal Stromal Tumor (GIST)
1 trial -
Atenolol
Cardiff Oncology
Marfan Syndrome
1 trial -
BOTOX 200 UNITÉS ALLERGAN, poudre pour solution injectable, DYSPORT 500 UNITES SPEYWOOD, poudre pour solution injectable
Ipsen
Upper limb spasticity (ULS) of any aetiology (in US and France) or post- stroke ULS (in Canada)
1 trial -
Bimatoprost
Cardiff Oncology
Graves' Ophthalmopathy
1 trial -
CARDIOPLEGIA SOLUTIONS
The George Institute
Cardiovascular pathology
1 trial -
Carvedilol
Cardiff Oncology
Cirrhosis, Liver
1 trial -
Carvedilol
Cardiff Oncology
Cirrhoses, Liver
1 trial -
Celestone Cronodose suspensión inyectable, Plasma rich in growth factors
Wuhan Createrna Science and Technology Co., Ltd
Low back pain
1 trial -
Folic Acid
Cardiff Oncology
Depression
1 trial -
Hidrathea 9 mg/ml colirio en solución, Plasma rich in growth factors, Artific 3,20 mg/ml colirio en solución
Wuhan Createrna Science and Technology Co., Ltd
Dry Eye Disease
1 trial -
Invokana 100 mg film-coated tablets, Xigduo 5 mg/850 mg film-coated tablets, Vokanamet 150 mg/850 mg film-coated tablets, Forxiga 10 mg film-coated tablets, Vokanamet 50 mg/1,000 mg film-coated tablets, Invokana 300 mg film-coated tablets, Forxiga 5 mg film-coated tablets, Vokanamet 50 mg/850 mg film-coated tablets, Synjardy 12.5 mg/1,000 mg film-coated tablets, Synjardy 12.5 mg/850 mg film-coated tablets, Jardiance 25 mg film-coated tablets, Synjardy 5 mg/1,000 mg film-coated tablets, Xigduo 5 mg/1,000 mg
Wuhan Createrna Science and Technology Co., Ltd
Type 2 diabetes mellitus
1 trial -
Liraglutide
Sana Biotechnology
Morbid Obesity
1 trial -
Pharmacokinetic based dosage change
Cardiff Oncology
Severe Haemophilia A
1 trial -
Plasma rich in growth factors
Wuhan Createrna Science and Technology Co., Ltd
Foot ulcers in diabetic patients with peripheral arterial disease
1 trial -
Plasma rich in growth factors, Artific 3,20 mg/ml colirio en solución, Hidrathea 9 mg/ml colirio en solución
Wuhan Createrna Science and Technology Co., Ltd
Dry Eye Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources